Corcept Therapeutics Inc CORT
We take great care to ensure that the data presented and summarized in this overview for CORCEPT THERAPEUTICS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CORT
View all-
Black Rock Inc. New York, NY16.5MShares$1.21 Billion0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.68MShares$705 Million0.01% of portfolio
-
Ingalls & Snyder LLC New York, NY7.72MShares$563 Million20.11% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny6.27MShares$457 Million0.65% of portfolio
-
Parallel Advisors, LLC3.87MShares$282 Million5.83% of portfolio
-
State Street Corp Boston, MA2.97MShares$216 Million0.01% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.09MShares$152 Million0.04% of portfolio
-
Geode Capital Management, LLC Boston, MA1.92MShares$140 Million0.01% of portfolio
-
Morgan Stanley New York, NY1.61MShares$118 Million0.01% of portfolio
-
Clearbridge Investments, LLC New York, NY1.17MShares$85.1 Million0.07% of portfolio
Latest Institutional Activity in CORT
Top Purchases
Top Sells
About CORT
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
Insider Transactions at CORT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 10
2025
|
Gillian Cannon |
SELL
Bona fide gift
|
Direct |
7,393
-100.0%
|
-
|
|
Sep 10
2025
|
Daniel N Swisher Jr |
SELL
Open market or private sale
|
Direct |
2,200
-100.0%
|
$158,400
$72.45 P/Share
|
|
Sep 10
2025
|
Daniel N Swisher Jr |
BUY
Exercise of conversion of derivative security
|
Direct |
2,200
+50.0%
|
$30,800
$14.08 P/Share
|
|
Sep 04
2025
|
Gillian Cannon |
SELL
Payment of exercise price or tax liability
|
Direct |
3,607
-32.79%
|
$252,490
$70.13 P/Share
|
|
Sep 04
2025
|
Gillian Cannon |
BUY
Exercise of conversion of derivative security
|
Direct |
11,000
+50.0%
|
$242,000
$22.99 P/Share
|
|
Sep 03
2025
|
Sean Maduck |
SELL
Payment of exercise price or tax liability
|
Direct |
233
-2.86%
|
$16,543
$71.38 P/Share
|
|
Sep 03
2025
|
Joseph Douglas Lyon |
SELL
Payment of exercise price or tax liability
|
Direct |
189
-1.81%
|
$13,419
$71.38 P/Share
|
|
Sep 03
2025
|
Gary Charles Robb Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
256
-1.85%
|
$18,176
$71.38 P/Share
|
|
Sep 03
2025
|
Atabak Mokari Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
144
-1.0%
|
$10,224
$71.38 P/Share
|
|
Sep 02
2025
|
Sean Maduck |
BUY
Grant, award, or other acquisition
|
Direct |
456
+2.76%
|
$15,960
$35.69 P/Share
|
|
Sep 02
2025
|
Sean Maduck |
SELL
Open market or private sale
|
Direct |
20,000
-46.77%
|
$1,400,000
$70.61 P/Share
|
|
Sep 02
2025
|
Sean Maduck |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+41.95%
|
$100,000
$5.05 P/Share
|
|
Sep 02
2025
|
Joseph Douglas Lyon |
BUY
Grant, award, or other acquisition
|
Direct |
400
+1.89%
|
$14,000
$35.69 P/Share
|
|
Sep 02
2025
|
Joseph Douglas Lyon |
SELL
Open market or private sale
|
Direct |
5,000
-16.76%
|
$350,000
$70.5 P/Share
|
|
Sep 02
2025
|
Joseph Douglas Lyon |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+24.92%
|
$65,000
$13.56 P/Share
|
|
Sep 02
2025
|
William Guyer Chief Development Officer |
SELL
Open market or private sale
|
Direct |
20,000
-52.86%
|
$1,400,000
$70.62 P/Share
|
|
Sep 02
2025
|
William Guyer Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+43.97%
|
$420,000
$21.65 P/Share
|
|
Sep 02
2025
|
Gary Charles Robb Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
502
+1.79%
|
$17,570
$35.69 P/Share
|
|
Sep 02
2025
|
Atabak Mokari Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
400
+1.37%
|
$14,000
$35.69 P/Share
|
|
Sep 02
2025
|
Joseph K Belanoff Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
40,000
-0.7%
|
$2,800,000
$70.76 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 32.6K shares |
|---|---|
| Bona fide gift | 4.64K shares |
| Exercise of conversion of derivative security | 1.17M shares |
| Other acquisition or disposition | 207K shares |
| Open market or private sale | 971K shares |
|---|---|
| Payment of exercise price or tax liability | 202K shares |
| Bona fide gift | 237K shares |
| Other acquisition or disposition | 7.25K shares |